Summary
Johnson & Johnson's (JNJ) 2019 10-K filing highlights a robust healthcare conglomerate with a diversified portfolio across Consumer, Pharmaceutical, and Medical Device segments. The company reported total sales of $82.1 billion, with a modest 0.6% increase year-over-year, driven by operational growth partially offset by currency headwinds. The Pharmaceutical segment showed notable growth, particularly from key products like STELARA® and IMBRUVICA®, while the Medical Device segment experienced a slight decline attributed to divestitures and market conditions. The Consumer segment saw minimal growth, with mixed performance across its franchises. The company's financial health remains strong, supported by substantial operating cash flow, though it continues to navigate significant litigation expenses, notably related to opioids and talc-based products. JNJ demonstrated continued commitment to returning value to shareholders through dividends and share repurchases, while also making significant investments in research and development ($11.4 billion) and strategic acquisitions ($5.8 billion) to fuel future growth. The company's financial outlook is influenced by ongoing healthcare reforms, pricing pressures, and the competitive landscape, particularly concerning patent expirations and biosimilar competition for key pharmaceutical products. Despite these challenges, JNJ's diversified business model and ongoing innovation pipeline position it to address evolving healthcare needs.
Financial Highlights
53 data points| Revenue | $82.06B |
| Cost of Revenue | $27.56B |
| Gross Profit | $54.50B |
| SG&A Expenses | $22.18B |
| Interest Expense | $318.00M |
| Net Income | $15.12B |
| EPS (Basic) | $5.72 |
| EPS (Diluted) | $5.63 |
| Shares Outstanding (Basic) | 2.65B |
| Shares Outstanding (Diluted) | 2.68B |
Key Highlights
- 1Total sales reached $82.1 billion, a 0.6% increase compared to the prior year, driven by operational growth.
- 2Pharmaceutical segment sales increased by 3.6% to $42.2 billion, with strong performance from STELARA® and IMBRUVICA®.
- 3Medical Device segment sales decreased by 3.8% to $26.0 billion, impacted by divestitures of LifeScan and Advanced Sterilization Products (ASP).
- 4Consumer segment sales increased by 0.3% to $13.9 billion, with growth in Beauty and OTC franchises partially offset by declines in Baby Care and Women's Health.
- 5Research and Development (R&D) investment was $11.4 billion, with a focus on innovation across all segments.
- 6The company incurred significant litigation expenses, including a $4 billion agreement in principle to settle opioid litigation.
- 7Johnson & Johnson increased its dividend for the 57th consecutive year, underscoring its commitment to shareholder returns.